Skip to main content

Site notifications

TRIMBOW (Emerge Health Pty Ltd)

Product name
TRIMBOW
Date registered
Evaluation commenced
Decision date
Approval time
155 working days (255)
Active ingredients
beclometasone dipropionate; formoterol (eformoterol) fumarate dihydrate; glycopyrronium bromide (glycopyrrolate)
Registration type
EOI
Indication
New Combination

TRIMBOW (pressurised inhalation solution) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).

Help us improve the Therapeutic Goods Administration site